TMO
NYSE · Life Sciences Tools & Services
Thermo Fisher Scientific Inc
$588.29
-7.60 (-1.28%)
Financial Highlights (FY 2026)
Revenue
44.59B
Net Income
6.71B
Gross Margin
40.9%
Profit Margin
15.0%
Rev Growth
-0.3%
D/E Ratio
0.74
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 40.9% | 40.9% | 57.1% | 57.1% |
| Operating Margin | 17.4% | 15.6% | 15.5% | 16.3% |
| Profit Margin | 15.0% | 14.3% | 13.3% | 12.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 44.59B | 44.71B | 92.02B | 88.63B |
| Gross Profit | 18.25B | 18.30B | 52.50B | 50.57B |
| Operating Income | 7.75B | 6.99B | 14.26B | 14.42B |
| Net Income | 6.71B | 6.05B | 12.22B | 10.68B |
| Gross Margin | 40.9% | 40.9% | 57.1% | 57.1% |
| Operating Margin | 17.4% | 15.6% | 15.5% | 16.3% |
| Profit Margin | 15.0% | 14.3% | 13.3% | 12.1% |
| Rev Growth | -0.3% | -0.3% | +9.1% | +0.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 47.22B | 47.22B | 92.45B | 87.66B |
| Total Equity | 64.04B | 64.04B | 89.94B | 92.99B |
| D/E Ratio | 0.74 | 0.74 | 1.03 | 0.94 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 8.80B | 8.38B | 18.73B | 15.75B |
| Free Cash Flow | — | — | 10.72B | 9.44B |